launch

Market Access

The new commercialisation playbook: What BIO 2026 taught eme...

BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs

Digital

The cliff was never the crisis: Pharma’s strategy problem

The patent cliff isn't the problem. It's the symptom.

Sales & Marketing

Pushing through barriers to commercial launch success, with ...

In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.

Sales & Marketing

Graphic illustration of hand holding launching rocket with dollar signs and a globe in the background

Execution drift: Why pharmaceutical go-to-market falls short...

Execution drift occurs when strategy, targeting, metrics, incentives, and behaviour gradually stop reinforcing one another.

Digital

Cracking the code: How European biotechs can win in the US m...

At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for emerging pharma and biotech...